Mandate

Vinge advises Cellink in directed new issues of shares of MSEK 946

Vinge has advised Cellink in connection with directed new issues of shares of approximately 5.9 million class B shares which will generate MSEK 946 for Cellink.

The subscription price has been set through a so‑called accelerating book building procedure performed by Carnegie and J.P. Morgan and corresponds to a discount of 1.7% compared to the share’s closing date rate on Nasdaq Stockholm. Almost 4.3 million shares have been issued by virtue of the authorization resolved by the general meeting and approximately 1.6 million shares have been issued conditional upon approval by an extraordinary general meeting. The purpose of the new issues of shares is, in part, financing of the cash element of the purchase price for the acquisition of Scienion Ag., and, in part, to create scope for Cellink’s continued M&A agenda.

Vinge’s team primarily consisted of Anders StridEdin Agic and Victoria Gunnerek.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026